Hepatitis A (HAV) is a common cause of viral hepatitis. However, with improved sanitation, hygiene measures and vaccination the number of cases has decreased by ~95% from 1996-2011. Routine vaccination with Hepatitis A vaccine was recommended for all children in the United State in 2006. Hepatitis A vaccine has a correlate of protection, this correlate is defined as achieving a detectable and quantifiable postvaccination HAV IgG level of ≥10 mIU/mL by standard assays. Hepatitis A vaccination is associated with robust and long-term protection with protection lasting upwards of 20 years. With increased vaccination and decreasing cases the CDC has recommended against routine use of HAV-IgM in asymptomatic patients. Within the military HAV immunity is assessed at accession with HAV IgG level. If service member is non-immune via serology, they receive hepatitis A vaccine at their accession site. Thus, all members of the uniformed services should have immunity to HAV. Persons who test positive for HAV antibodies (HAV-IgG) are considered immune. Subsequent testing for HAV is not advised. HAV-IgM testing is only recommended when there is suspicion for acute HAV infection in a non-immune person, based on acute hepatitis signs or symptoms or exposure to HAV. False-positive HAV-IgM results have been relatively common and problematic when evaluated in persons without hepatitis. There are several reasons for false-positive HAV-IgM results, but clinical follow-up to explore this issue would only be appropriate in a patient with clinical hepatitis. Healthcare providers should limit the use of Hepatitis A IgM to patients with clinical evidence of hepatitis or recent exposure to Hepatitis A virus.